DK3468944T3 - Co-krystaller af natriumbenzoat og anvendelser deraf - Google Patents

Co-krystaller af natriumbenzoat og anvendelser deraf Download PDF

Info

Publication number
DK3468944T3
DK3468944T3 DK17812704.9T DK17812704T DK3468944T3 DK 3468944 T3 DK3468944 T3 DK 3468944T3 DK 17812704 T DK17812704 T DK 17812704T DK 3468944 T3 DK3468944 T3 DK 3468944T3
Authority
DK
Denmark
Prior art keywords
crystals
sodium benzoate
benzoate
sodium
Prior art date
Application number
DK17812704.9T
Other languages
Danish (da)
English (en)
Inventor
Guochuan Emil Tsai
Ching-Cheng Wang
Tien-Lan Hsieh
Yuan-Chun Lo
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Application granted granted Critical
Publication of DK3468944T3 publication Critical patent/DK3468944T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/10—Sorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C07C57/44—Cinnamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17812704.9T 2016-06-13 2017-06-13 Co-krystaller af natriumbenzoat og anvendelser deraf DK3468944T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349578P 2016-06-13 2016-06-13
PCT/CN2017/088045 WO2017215593A1 (en) 2016-06-13 2017-06-13 Co-crystals of sodium benzoate and uses thereof

Publications (1)

Publication Number Publication Date
DK3468944T3 true DK3468944T3 (da) 2023-02-06

Family

ID=60663996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17812704.9T DK3468944T3 (da) 2016-06-13 2017-06-13 Co-krystaller af natriumbenzoat og anvendelser deraf

Country Status (13)

Country Link
US (2) US11008277B2 (show.php)
EP (1) EP3468944B1 (show.php)
JP (1) JP6958922B2 (show.php)
KR (1) KR102403048B1 (show.php)
CN (1) CN109563018A (show.php)
CA (1) CA3027297A1 (show.php)
DK (1) DK3468944T3 (show.php)
ES (1) ES2936094T3 (show.php)
FI (1) FI3468944T3 (show.php)
IL (1) IL263492B (show.php)
MX (1) MX2018015397A (show.php)
TW (1) TWI671287B (show.php)
WO (1) WO2017215593A1 (show.php)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102488927B1 (ko) 2016-06-13 2023-01-13 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
US11826326B2 (en) * 2017-11-22 2023-11-28 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
US12478598B2 (en) 2019-02-25 2025-11-25 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
CA3180941C (en) 2020-06-01 2024-01-02 Rajaram Samant Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US4731379A (en) * 1983-12-07 1988-03-15 H.S.C. Corporation Flea eradicator
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
CA2058455A1 (en) * 1990-12-21 1992-06-22 Mark W. Collison Synergistic effect of lantibiotics in combination with selected agents against gram positive bacteria
JPH06502184A (ja) * 1991-02-22 1994-03-10 シャピロ，ハワード　ケイ． 神経性疾病の症候や原因上関係のある症候の治療のための薬用化合物の使用
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5441981A (en) * 1994-01-27 1995-08-15 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
DE19925425A1 (de) * 1999-06-02 2000-12-07 Wessollek Heimo Mittel zur Entkeimung bzw. keimreduzierenden Gestaltung von Reinigungs-, Sanitär- und Toilettenartikeln sowie kosmetischen Artikeln, Körperpflegeartikeln und dergleichen verkeimungsgefährdeten Gegenständen
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
DE60134899D1 (de) 2000-08-14 2008-08-28 Teva Pharma Herstellung von Risperidon
AU2002247939B2 (en) 2001-01-16 2007-01-25 Serono Genetics Institute S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20100311701A1 (en) 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004037234A2 (en) 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004064762A2 (en) * 2003-01-21 2004-08-05 S.S.C.I. Inc. Novel cocrystallization
CA2798615A1 (en) * 2003-01-21 2004-08-05 Aptuit (West Lafayette), Llc Novel cocrystallization of hydrochloric acid salt of an active agent
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
CA2527284A1 (en) 2003-06-02 2005-01-06 Laurent Lecanu Methods and compositions for modulating serum cortisol levels
NZ548213A (en) 2003-12-29 2010-05-28 Sepracor Inc Benzo[d]isoxazol-3-ol DAAO inhibitors
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
DK1742624T3 (da) 2004-02-18 2010-03-08 Sepracor Inc Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
WO2005117911A2 (en) 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2505808A1 (en) * 2005-05-02 2006-11-02 Julie Danielle Globus Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045547A1 (en) * 2006-07-07 2008-02-21 Lippa Arnold S Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
EP2167043A4 (en) * 2007-06-06 2013-05-01 Univ South Florida NEW USE CO-CRYSTAL COMPOSITIONS
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
US20130338199A1 (en) 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
MX2011002312A (es) * 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
JP2010106001A (ja) * 2008-10-31 2010-05-13 Theravalues Corp Ｐｐａｒ活性化剤
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
EP3656765B1 (en) 2010-07-23 2021-04-14 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
JP2014508814A (ja) 2011-03-24 2014-04-10 ユニバーシティ・オブ・サウス・フロリダ リチウム組成物
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
US9120766B2 (en) * 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
AU2013239114B2 (en) * 2012-03-30 2017-07-20 Nuformix Limited Tranilast compositions and cocrystals
RS63411B1 (sr) * 2013-04-19 2022-08-31 Univ South Florida Organska anjonska litijum-jonska kokristalna jedinjenja i supstance
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
WO2015058067A1 (en) * 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
US10888555B2 (en) * 2013-12-13 2021-01-12 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
WO2015147742A1 (en) * 2014-03-24 2015-10-01 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment
CN103992320A (zh) * 2014-05-26 2014-08-20 南京工业大学 一种混悬结晶制备药物共晶的方法
CN106536501A (zh) * 2014-05-27 2017-03-22 R.J.雷诺兹烟草公司 烟碱盐、共晶体和盐共晶体络合物
US9896429B2 (en) * 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
JP2017536363A (ja) * 2014-11-19 2017-12-07 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症治療のための組成物及び方法
RU2582962C1 (ru) 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
KR102488927B1 (ko) * 2016-06-13 2023-01-13 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
MX2018015758A (es) 2016-06-14 2019-05-20 Aemerge Llc Reciclaje de hidrocarburos de gases de carbonizacion calientes.
US10064833B2 (en) * 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US9877942B1 (en) * 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
US20190076472A1 (en) * 2017-09-14 2019-03-14 CT Development One, LLC Hyperammonemia therapy for children suffering from urea cycle disorders
US10098861B1 (en) * 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Also Published As

Publication number Publication date
US20190169110A1 (en) 2019-06-06
RU2019100436A3 (show.php) 2020-07-14
US20210340094A1 (en) 2021-11-04
US11008277B2 (en) 2021-05-18
RU2019100436A (ru) 2020-07-14
EP3468944A4 (en) 2020-02-12
FI3468944T3 (fi) 2023-01-31
JP2019518756A (ja) 2019-07-04
EP3468944A1 (en) 2019-04-17
JP6958922B2 (ja) 2021-11-02
IL263492B (en) 2021-08-31
EP3468944B1 (en) 2022-11-16
KR102403048B1 (ko) 2022-05-26
CA3027297A1 (en) 2017-12-21
KR20190018477A (ko) 2019-02-22
MX2018015397A (es) 2019-08-16
US11731928B2 (en) 2023-08-22
TWI671287B (zh) 2019-09-11
CN109563018A (zh) 2019-04-02
TW201802065A (zh) 2018-01-16
ES2936094T3 (es) 2023-03-14
WO2017215593A1 (en) 2017-12-21
IL263492A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3667980T3 (da) Indikation og modtagelse af ressourceposition
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3289168T3 (da) Forsegling og aktivering af borehul
DK3725357T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3364958T3 (da) Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
EP3529229A4 (en) POLYMORPHIC FORMS OF SODIUM BENZOATE AND THEIR USES
DK3457851T3 (da) Derivater af sobetirom
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol
DK3474822T3 (da) Formuleringer af brincidofovir
DK3347006T3 (da) Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3398598T3 (da) Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
DK3390422T3 (da) Krystalformer af lnt
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK2958573T3 (da) Farmaceutiske formuleringer af nitrit og anvendelser deraf